<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

SC 144 hydrochloride

產(chǎn)品貨號

Axon 2324 CAS [917497-70-2] MF C16H111FN6O.HClMW 358.76 Purity: 99% Soluble in DMSO Description The first-in-class small-molecule gp130 inhibitor with oral activity in ovarian cancer (IC50 values 0.43-0.95 μM for a range of human ovarian cancer cell lines). SC144 binds gp130, induces gp130 phosphorylation and deglycosylation, abrogates Stat3 phosphorylation and nuclear translocation, and further inhibits the expression of downstream target genes. References Certificates Categories Extra info C. Plasencia et al. Discovery of a novel quinoxalinhydrazide with a broad-spectrum anticancer activity. Cancer Biol Ther. 2009 Mar;8(5):458-65. ? S. Xu et al. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Mol Cancer Ther. 2013 Jun;12(6):937-49. ? T. Oshima et al. Combination effects of SC144 and cytotoxic anticancer agents. Anticancer Drugs. 2009 Jun;20(5):312-20. ? F. Grande et al. Synthesis and antitumor activities of a series of novel quinoxalinhydrazides. Bioorg Med Chem. 2007 Jan 1;15(1):288-94. Certificate of Analysis Material Safety Data Sheet Angiogenesis Apoptosis Cell Cycle Regulation Cell Signaling & Oncology Diabetes & Metabolism MAPK JAK-STAT PI3K-Akt-mTOR Type I gp130 The first-in-class small-molecule gp130 inhibitor Chemical name N'-(7-fluoropyrrolo[1,2-a]quinoxalin-4-yl)pyrazine-2-carbohydrazide hydrochloride Parent CAS No. [895158-95-9] Order Size Unit Price Stock 10 mg €135.00 In Stock

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

SC 144 hydrochloride

Based on 12 reference(s) in Google Scholar 9 10 12

Axon 2324

CAS [917497-70-2]

MF C16H111FN6O.HCl
MW 358.76

Purity: 99%
Soluble in DMSO

SC 144 hydrochloride

Description

The first-in-class small-molecule gp130 inhibitor with oral activity in ovarian cancer (IC50 values 0.43-0.95 μM for a range of human ovarian cancer cell lines). SC144 binds gp130, induces gp130 phosphorylation and deglycosylation, abrogates Stat3 phosphorylation and nuclear translocation, and further inhibits the expression of downstream target genes.

C. Plasencia et al. Discovery of a novel quinoxalinhydrazide with a broad-spectrum anticancer activity. Cancer Biol Ther. 2009 Mar;8(5):458-65.

S. Xu et al. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Mol Cancer Ther. 2013 Jun;12(6):937-49.

T. Oshima et al. Combination effects of SC144 and cytotoxic anticancer agents. Anticancer Drugs. 2009 Jun;20(5):312-20.

F. Grande et al. Synthesis and antitumor activities of a series of novel quinoxalinhydrazides. Bioorg Med Chem. 2007 Jan 1;15(1):288-94.

Certificate of Analysis
Material Safety Data Sheet

Angiogenesis Apoptosis Cell Cycle Regulation Cell Signaling & Oncology Diabetes & Metabolism MAPK JAK-STAT PI3K-Akt-mTOR Type I gp130

The first-in-class small-molecule gp130 inhibitor

Chemical name

N'-(7-fluoropyrrolo[1,2-a]quinoxalin-4-yl)pyrazine-2-carbohydrazide hydrochloride

Parent CAS No.

[895158-95-9]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>